Subtype
Neuroblastic Tumor
CI-CAN-00001274Explore in graph →
137 active trials3 approved drugs28 evidence items
- NCIt
- C6963
Loading cancer entity…
Subtype
CI-CAN-00001274Explore in graph →
Clinical trials
619 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03015844 | A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma | available | — | — | Northwell HealthOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01370330 | 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol | available | — | — | Kieuhoa VoOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT01163383 | 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol | available | — | — | John MarisOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03581240 | An Intermediate Expanded Use Trial of DFMO | available | — | — | Giselle ShollerOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT01590680 | Expanded Access Protocol Using 131I-MIBG | available | — | — | Jubilant DraxImage Inc.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials